Recently, increased p-ERK1/2 levels were reported in ovarian cancer models rendered resistant to BET inhibition, which was suggested to result from transcriptional up-regulation of receptor tyrosine kinases (RTKs) that activate MEK/ERK signaling7. This evidence concerns the gene MAP2K7 and ovarian carcinoma.